



Efficacy of bedaquiline, alone or in combination with imipenem, against *Mycobacterium abscessus* C3HeB/FeJ mice

Vincent Le Moigne, Clément Raynaud, Flavie Moreau, Christian Dupont, Jérôme Nigou, Olivier Neyrolles, Laurent Kremer, Jean-Louis Herrmann

► To cite this version:

Vincent Le Moigne, Clément Raynaud, Flavie Moreau, Christian Dupont, Jérôme Nigou, et al.. Efficacy of bedaquiline, alone or in combination with imipenem, against *Mycobacterium abscessus* C3HeB/FeJ mice. *Antimicrobial Agents and Chemotherapy*, 2020, 64 (6), 10.1128/AAC.00114-20 . hal-03032987

HAL Id: hal-03032987

<https://cnrs.hal.science/hal-03032987>

Submitted on 1 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Efficacy of bedaquiline, alone or in combination with imipenem,
against *Mycobacterium abscessus* in C3HeB/FeJ mice**

Vincent Le Moigne^{1,*}, Clément Raynaud², Flavie Moreau³, Christian Dupont², Jérôme Nigou³, Olivier Neyrolles³, Laurent Kremer^{2,4} and Jean-Louis Herrmann^{1,5}.

(1) Université Paris-Saclay, UVSQ, INSERM, Infection et Inflammation (U1173), Montigny le Bretonneux, France.

(2) Institut de Recherche en Infectiologie de Montpellier, Centre National de la Recherche Scientifique UMR 9004, Université de Montpellier, Montpellier, France

(3) Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse, France.

(4) INSERM, IRIM, 34293 Montpellier, France

(5) AP-HP, GHU Paris-Saclay, Hôpital Raymond Poincaré, Garches, France.

(*) Correspondence to: Vincent Le Moigne: vincent.le-moigne@uvsq.fr

ABSTRACT (75 words)

Mycobacterium abscessus lung infections remain difficult to treat. Recent studies have recognized the power of new combinations of antibiotics such as bedaquiline and imipenem although *in vitro* data have questioned this combination. We report that the efficacy of the bedaquiline plus imipenem treatment relies essentially on the activity of bedaquiline in a C3HeB/FeJ mice model of infection with a rough variant of *M. abscessus*. The addition of imipenem contributed at clearing the infection in the spleen.

Note (1074 words)

Mycobacterium abscessus is a rapidly growing mycobacterial species, whose infections remain very difficult to treat, due to the limited panel of available antibiotics (1). Among them, the β -lactams, imipenem (IPM) and ceftazidime (FOX), are part of the *M. abscessus* multidrug therapy along with amikacin (AMK) and clarithromycin (CLR) (2-5). In addition, the development of specific β -lactamase inhibitors, enhancing the efficacy of IPM *in vitro* and *in vivo*, broadens the use of IPM in *M. abscessus* drug therapy (6-8). Other studies highlighted the potential of testing new drug combinations that include IPM and are associated with increased efficacy against *M. abscessus* (6, 9, 10), yet questioning the relevance of the bedaquiline (BDQ) plus IPM combination (11). BDQ targets the ATP synthase and exhibits activity against a wide panel of *M. abscessus* clinical isolates *in vitro* and in infected zebrafish, although its effect is bacteriostatic only (12). A recent study suggested that, by reducing the intracellular pool of ATP in *M. abscessus*, BDQ suppresses the effect of IPM and FOX, although the effect of the BDQ plus IPM combination was considered additive (11). This led the investigators to conclude that the addition of BDQ to a β -lactam-containing regimen may negatively affect the treatment outcome (11). In comparison, data from the hollow fiber model highlight that β -lactam is the most active and important part of the *M. abscessus* regimen (13). That these studies focused exclusively on the interaction of β -lactams and BDQ *in vitro*, confirmatory results in a pre-clinical animal model are warranted.

Herein, we explored the therapeutic efficacy of BDQ or IPM, alone or in combination, using the immunocompetent C3HeB/FeJ mouse model of *M. abscessus* infection. C3HeB/FeJ mice are highly susceptible to mycobacterial infections, particularly to *Mycobacterium tuberculosis* due to a deletion on the *Ipr1* (Intracellular pathogen resistance 1) gene located in the locus called *sst1* (14, 15). All animal experiments were performed according to ethical guidelines and with ethical committee (N°047 with agreement A783223) agreement APAFIS#11465.

First, we evaluated, the *in vitro* interaction between BDQ and several β -lactams or CLR against *M. abscessus* CIP104536 strain in cation-adjusted Mueller-Hinton broth (CaMHB) (Becton-Dickinson, Le Pont-de-Claix, France) using a 2-dimensional microdilution checkerboard method, as previously described (16-19). Our results confirm that the β -lactam plus BDQ combinations are indifferent, as it is the case with the CLR plus BDQ combination (Table 1).

Next, the performances of pulmonary and intravenous (IV) infection routes were compared in C3HeB/FeJ mice. Mice were infected intratracheally using agar bead-embedded bacteria to maintain a persistent infection, as reported previously for *Pseudomonas aeruginosa* (20). A significant increase in mortality was noticed when mice were infected intratracheally with a solution of agar beads containing 2.10^5 CFUs/mouse in 50 μ l, leading only to 40% of mouse survival at 14 days post-infection (dpi) (see Fig. S1A in the supplemental material) correlated with an important increase in the CFU at 14 dpi suggesting accelerated bacterial growth in the lungs (Fig. S1B). In contrast, persistence occurs for up to 25 days after IV infection with 10^6 CFU/mouse as evidenced by CFU counting after plating of the organ homogenates (Fig. 1 and Fig. S2A and S2B) although as soon as the injected dose is less than 10^6 CFU, persistence in the organs is reduced (Fig. S2B). This represents an important asset over previously described murine models, characterized by a more rapid bacterial clearance (21-23).

The IV route of infection was subsequently used to evaluate and compare the activity of BDQ and AMK. Because AMK is bactericidal against *M. abscessus* while BDQ is bacteriostatic *in vitro*, we wondered whether BDQ would be more effective than AMK in an *in vivo* infection model. CFU were significantly reduced in mice receiving 30 mg/kg BDQ (oral administration) as compared to mice treated with 150 mg/kg AMK (subcutaneous administration) in the lungs and the spleen at 12 and 25 dpi (Fig. 2A and 2B). No significant differences were observed between the BDQ- or AMK-treated animals in the spleen at 12 dpi, but bacterial loads in these two groups were significantly lower compared to the control group (oral administration of DMSO) (Fig. 2C).

The efficacy of BDQ in this infection model prompted us to compare it with IPM (subcutaneous administration) either alone or as a companion drug, for 15 days of treatment. No significant differences were noticed between the animals treated with BDQ alone and the animals treated with BDQ plus IPM at 12 and 20 dpi, with the exception of the liver at 12 dpi (Fig. 3A to 3C), indicating that the overall activity of the BDQ plus IPM combination was mainly due to the intrinsic activity of BDQ. In general, BDQ alone or in combination with IPM exhibited an increased activity as compared to IPM in the liver and spleen but not in the lungs (Fig. 3). The spleens of treated and untreated mice were weighed as an additional marker of the effectiveness of the various treatments. These measures indicated that only treatments with BDQ plus IPM or IPM alone were associated with lower spleen weights, as compared to those of the untreated or BDQ-treated mice (Fig. 3D). Collectively, the reduced

bacterial burden, together with the lower spleen weights represent a marker for improved outcome of the infection.

BDQ is a diarylquinoline approved by the Food and Drug Administration and the European Medicines Agency for the treatment of multidrug-resistant tuberculosis. It is bacteriostatic against *M. abscessus in vitro*, displaying MIC₅₀ of 0.125 µg/ml and a MIC₉₀ > 16 µg/ml, and ECOFF values demonstrates that BDQ exhibits moderate activity (16, 24). Discordant results regarding the efficacy of BDQ were generated in various immunocompromised mouse models, raising the question of the influence of immunosuppression on antibiotic efficacy (25, 26). However, efficient responses to BDQ were observed in other animal models, such as zebrafish (12). Two studies reported poor or negative results for BDQ administration against NTM infected patients (27, 28). However, recent studies showed that the activity of BDQ can be potentiated with adjunctive therapy, by so improving BDQ-based treatments (16, 29). This study provides evidence that the BDQ plus IPM combination remains superior to IPM alone and equivalent to BDQ alone as judged by the comparable bacterial clearance in the spleens of the mice treated with BDQ plus IPM as compared to BDQ alone.

In summary, the IPM plus BDQ combination enhances the clearance of the infection. This supports also the importance of evaluating antibiotic activity in combination rather than separately against this highly drug-resistant mycobacterium.

ACKNOWLEDGMENTS

Bedaquiline was a kind gift from Dr C. Happel (NIH AIDS Reagent Program, USA) and from Dr N. Lounis (from Janssen Pharmaceuticals, Beerse, Belgium). We acknowledged Pr N. Véziris and Pr J. van Ingen for helpful comments and critical reading of the manuscript. We thank the members of the Genotoul core facility ANEXPLO (IPBS, Toulouse) for animal experiments. This study was supported by INSERM, University of Versailles Saint Quentin en Yvelines, by the Association Gregory Lemarchal and Vaincre la Mucoviscidose (RIF20180502320) to LK and JLH, the Agence Nationale de la Recherche (MyCat ANR-15-CE18-0007-02) to LK, by CNRS, University of Toulouse, Agence Nationale de la Recherche /Programme d'Investissements d'Avenir (ANR-11-EQUIPEX-0003), and the Bettencourt Schueller Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

131 **AUTHOR CONTRIBUTIONS STATEMENT**

132

133 JLH, JN and ON designed the project and experiments; VLM, CR, FM and CD performed the

134 experiments; VLM, CR, JN, ON, LK and JLH wrote and corrected the manuscript.

135

REFERENCES

1. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ. 2019. *Mycobacterium abscessus* pulmonary disease: individual patient data meta-analysis. *Eur Respir J* 54:pii: 1801991.
2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 175:367-416.
3. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. 2017. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). *Thorax* 72:ii1-ii64.
4. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. 2016. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. *Thorax* 71:88-90.
5. Lefebvre AL, Le Moigne V, Bernut A, Veckerlé C, Compain F, Herrmann JL, Kremer L, Arthur M, Mainardi JL. 2017. Inhibition of the β -Lactamase Bla_{Mab} by Avibactam Improves the *In Vitro* and *In Vivo* Efficacy of Imipenem against *Mycobacterium abscessus*. *Antimicrob Agents Chemother* 61:e02440-16.
6. Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL. 2019. *In Vitro* Activity of the New β -Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β -Lactams against *Mycobacterium abscessus* Complex Clinical Isolates. *Antimicrob Agents Chemother* 63:e02623-18.

7. Dubée V, Bernut A, Cortes M, Lesne T, Dorcène D, Lefebvre AL, Hugonnet JE, Gutmann L, Mainardi JL, Herrmann JL, Gaillard JL, Kremer L, Arthur M. 2015. β -Lactamase inhibition by avibactam in *Mycobacterium abscessus*. J Antimicrob Chemother 70:1051-1058.
8. Dubée V, Soroka D, Cortes M, Lefebvre AL, Gutmann L, Hugonnet JE, Arthur M, Mainardi JL. 2015. Impact of β -lactamase inhibition on the activity of ceftaroline against *Mycobacterium tuberculosis* and *Mycobacterium abscessus*. Antimicrob Agents Chemother 59:2938-2941.
9. Le Run E, Arthur M, Mainardi JL. 2019. In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against *Mycobacterium abscessus*. Antimicrob Agents Chemother 63:e01915-18.
10. Le Run E, Arthur M, Mainardi JL. 2018. In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against *Mycobacterium abscessus*. Antimicrob Agents Chemother 62:e00623-18.
11. Lindman M, Dick T. 2019. Bedaquiline eliminates bactericidal activity of β -lactams against *Mycobacterium abscessus*. Antimicrob Agents Chemother 63:e00827-19.
12. Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann JL, Pethe K, Kremer L. 2017. Bedaquiline inhibits the ATP synthase in *Mycobacterium abscessus* and is effective in infected zebrafish. Antimicrob Agents Chemother 61:e01225-17.
13. Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. 2016. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary *Mycobacterium abscessus* Infection. Antimicrob Agents Chemother 60:6374-6376.
14. Kramnik I, Dietrich WF, Demant P, Bloom BR. 2000. Genetic control of resistance to experimental infection with virulent *Mycobacterium tuberculosis*. Proc Natl Acad Sci U S A 97:8560-8565.
15. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772.
16. Ruth MM, Sengen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J. 2019. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 74:935-943.

17. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. *J Antimicrob Chemother.* 52:1.
18. Li W, Sanchez-Hidalgo A, Jones V, de Moura VC, North EJ, Jackson M. 2017. Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds *In Vitro.* *Antimicrob Agents Chemother.* 61:e02399-16.
19. Clinical and Laboratory Standards Institute (CLSI). 2018. Susceptibility Testing of *Mycobacteria, Nocardiae* spp., and Other Aerobic Actinomycetes. 3rd ed. CLSI standard M24. Wayne, PA.
20. Cigana C, Lorè NI, Riva C, De Fino I, Spagnuolo L, Sipione B, Rossi G, Nonis A, Cabrini G, Bragonzi A. 2016. Tracking the immunopathological response to *Pseudomonas aeruginosa* during respiratory infections. *Sci Rep* 6:21465.
21. Bernut A, Le Moigne V, Lesne T, Lutfalla G, Herrmann JL, Kremer L. 2014. *In vivo* assessment of drug efficacy against *Mycobacterium abscessus* using the embryonic zebrafish test system. *Antimicrob Agents Chemother* 58:4054-4063.
22. Le Moigne V, Rottman M, Goulard C, Barteau B, Poncin I, Soismier N, Canaan S, Pitard B, Gaillard JL, Herrmann JL. 2015. Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: the *Mycobacterium abscessus* model. *Vaccine* 33:2118-2124.
23. Ordway D, Henao-Tamayo M, Smith E, Shanley C, Harton M, Troudt J, Bai X, Basaraba RJ, Orme IM, Chan ED. 2008. Animal model of *Mycobacterium abscessus* lung infection. *J Leukoc Biol* 83:1502-1511.
24. Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. 2017. *In Vitro* Activity of Bedaquiline against Nontuberculous *Mycobacteria* in China. *Antimicrob Agents Chemother* 61:e02627-16.
25. Lerat I, Cambau E, Roth Dit Bettoni R, Gaillard JL, Jarlier V, Truffot C, Veziris N. 2014. *In vivo* evaluation of antibiotic activity against *Mycobacterium abscessus*. *J Infect Dis* 209:905-912.
26. Obregón-Henao A, Arnett KA, Henao-Tamayo M, Massoudi L, Creissen E, Andries K, Lenaerts AJ, Ordway DJ. 2015. Susceptibility of *Mycobacterium abscessus* to antimycobacterial drugs in preclinical models. *Antimicrob Agents Chemother* 59:6904-6912.
27. Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. 2015. Preliminary Results of Bedaquiline as Salvage

Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest
148:499-506.

28. Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van Ingen J. 2019. Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary *Mycobacterium avium* complex disease. Eur Respir J. 54:1900118.

29. Viljoen A, Raynaud C, Johansen MD, Roquet-Banères F, Herrmann JL, Daher W, Kremer L. 2019. Verapamil Improves the Activity of Bedaquiline against *Mycobacterium abscessus* *In Vitro* and in Macrophages. Antimicrob Agents Chemother 63: e00705-719.

30. Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, Orme IM, Basaraba RJ. 2007. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 51:3338-3345.

Table 1. Interaction between bedaquiline and other drugs against *M. abscessus* CIP104536^T

Compound	MIC* (mg/l)	Interaction with BDQ		
		FICI ^{\$} (mean)	SD	Outcome
BDQ	0.125	-	-	-
IPM	16 ^{&}	0.55	±0.06	Indifferent [£]
FOX	32	0.52	±0.03	Indifferent
CLR	2	0.61	±0.09	Indifferent
AMP	>512	0.57	±0.02	Indifferent

(*) MIC were evaluated by REMA checkerboard assay in cation-adjusted Mueller-Hinton broth (CaMHB) (Becton-Dickinson, Le Pont-de-Claix, France). 10⁵ bacteria were diluted in Mueller-Hinton media (Sigma-Aldrich). Plates were incubated for 3 days at 30°C then 20 µL (10% v/f) of Resazurin 0.025% were added to the wells and plates were incubated overnight at 30°C.

(\$) The fractional inhibitory concentration index (FICI) was calculated as follows: FICI = (MIC drug A in combination/MIC drug A alone) + (MIC drug B in combination/MIC drug B alone), where drug A was bedaquiline (BDQ) and drug B was clarithromycin (CLR, Sigma-Aldrich, France), imipenem (IPM, Mylan S.A.S, France), ceftiofur (FOX, Panpharma, France) or ampicillin (AMP, Euromedex, France).

(£) Interaction between the two compounds was defined as synergistic when FICI value was ≤0.5, indifferent when 0.5 < FICI ≤4, and antagonistic when FICI was >4.

(&) Values showed in the table are the mean of four independent experiments ±SD.

270

271 Legend to figures

272 **Figure 1.** Bacterial persistence of *M. abscessus* CIP 104536^T (rough variant) in the lungs,
273 spleen and liver of C3HeB/FeJ mice after infection in the tail vein with 10⁶ CFU/mouse in a
274 total volume of 200 µl of water containing 0.9% sodium chloride. The following day, three
275 mice were euthanized and whole organs were harvested to determine baseline bacterial
276 burden. Mouse lungs, spleens and livers were homogenized, serially diluted and plated onto
277 VCAT (Vancomycin, Colistin sulfate, Amphotericin B, and Trimethoprim) chocolate agar
278 plates (BioMérieux, France) and incubated for 5-6 days at 37°C prior to CFU count. Results
279 are expressed as the log₁₀ units of CFU at 1, 12 and 25 dpi.

280

281

282

283 **Figure 2.** *M. abscessus* R-infected C3HeB/FeJ mice (9.2×10⁵ CFU/mouse) treated with
284 Bedaquiline (BDQ) or Amikacin (AMK). Bacterial counts in the lungs (A), liver (B) and
285 spleen (C) of C3HeB/FeJ mice infected IV, as described in Fig. 1. Antibiotic treatment began
286 at 2 dpi. Mice were treated starting on day 2 for 7 days (D12) or 17 days (D25) by daily
287 subcutaneous injections of 150 mg/kg AMK (Mylan laboratories) in saline solution or daily
288 oral gavage of 30 mg/kg BDQ at in a total volume of 200 µl (BDQ solution in DMSO was
289 diluted in 20 % 2-hydroxypropyl-β-cyclodextrin). A control group received a daily
290 subcutaneous injection of saline and oral gavage of DMSO containing 20 % 2-hydroxypropyl-
291 β-cyclodextrin. All solutions were administered five times weekly for latter time point. Mice
292 were euthanized 3 days after antibiotic cessation to allow antibiotic clearance. Furthermore,
293 given the long half-life and high protein binding capacity of BDQ, spleens, livers and lungs
294 from drug-treated and control mice were homogenized in water supplemented with 10%
295 bovine serum albumin (30) before dilution. Experimental groups of mice were evaluated for
296 bacterial burden on day 1 (before treatment started), 12 and 25 as described in Fig. 1. n = 5
297 mice were used per experiment and bacterial load in each group are expressed as log₁₀ units of
298 CFU (± SD) cells. Differences between means were analyzed by two-way ANOVA and the
299 Tukey post-test, allowing multiple comparisons. n.s. = non-significant, * *P* < 0.05, ** *P* < 0.01,
300 *** *P* < 0.001, **** *P* < 0.0001. Experiment was realized once.

301

302

303

304 **Figure 3.** *M. abscessus* R-infected C3HeB/FeJ mice treated (2.7×10⁵ CFU/mouse) by
305 Bedaquiline (BDQ), Imipenem (IPM) or BDQ plus IPM. Bacterial loads in the lungs (A),
306 liver (B) and spleen (C) were determined as reported in Fig. 1. Relative weight of spleen to
307 mouse weight are shown in (D). Antibiotic treatment began 2 days after infection. Mice were
308 treated starting on day 2 for 7 days (D12) or 13 days (D20) with twice daily (i.e. every 12 h)
309 subcutaneous injection of IPM (MSD laboratories, France) in saline solution at 100 mg/kg or
310 daily oral gavage of BDQ as described in Fig. 2 or both IPM plus BDQ. Experimental groups
311 of mice were evaluated for bacterial burden on day 1 (before treatment started), 12 and 20 as
312 described in Fig. 1. (D) Mouse spleens were weighed at 1, 12 and 20 dpi. The value
313 represents the relative weight of each spleen relative to the weight of the mouse from which
314 they were collected. n = 5 mice were used per experiment and bacterial load in each group are
315 expressed as log₁₀ units of CFU (± SD) cells. Differences between means were analyzed by
316 two-way ANOVA and the Tukey post-test, allowing multiple comparisons. n.s. = non-

317 significant, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Experiment was realized
318 once.
319

Figure 1






Figure 1. Bacterial persistence of *M. abscessus* CIP 104536^T (rough variant) in the lungs, spleen and liver of C3HeB/FeJ mice after infection in the tail vein with 10⁶ CFU/mouse in a total volume of 200 µl of water containing 0.9% sodium chloride. The following day, three mice were euthanized and whole organs were harvested to determine baseline bacterial burden. Mouse lungs, spleens and livers were homogenized, serially diluted and plated onto VCAT (Vancomycin, Colistin sulfate, Amphotericin B, and Trimethoprim) chocolate agar plates (BioMérieux, France) and incubated for 5-6 days at 37°C prior to CFU count. Results are expressed as the log₁₀ units of CFU at 1, 12 and 25 dpi.

Figure 2


A



B



C



- control DMSO (p.o.)
- △ Bedaquiline 30 mg/kg (p.o.)
- ▲ Amikacin 150 mg/kg (s.c.)

Figure 2. *M. abscessus* R-infected C3HeB/FeJ mice (9.2×10^5 CFU/mouse) treated with Bedaquiline (BDQ) or Amikacin (AMK). Bacterial counts in the lungs (A), liver (B) and spleen (C) of C3HeB/FeJ mice infected IV, as described in Fig. 1. Antibiotic treatment began at 2 dpi. Mice were treated starting on day 2 for 7 days (D12) or 17 days (D25) by daily subcutaneous injections of 150 mg/kg AMK (Mylan laboratories) in saline solution or daily oral gavage of 30 mg/kg BDQ at in a total volume of 200 μ l (BDQ solution in DMSO was diluted in 20 % 2-hydroxypropyl- β -cyclodextrin). A control group received a daily subcutaneous injection of saline and oral gavage of DMSO containing 20 % 2-hydroxypropyl- β -cyclodextrin. All solutions were administered five times weekly for latter time point. Mice were euthanized 3 days after antibiotic cessation to allow antibiotic clearance. Furthermore, given the long half-life and high protein binding capacity of BDQ, spleens, livers and lungs from drug-treated and control mice were homogenized in water supplemented with 10% bovine serum albumin (30) before dilution. Experimental groups of mice were evaluated for bacterial burden on day 1 (before treatment started), 12 and 25 as described in Fig. 1. n = 5 mice were used per experiment and bacterial load in each group are expressed as log₁₀ units of CFU ($\pm$ SD) cells. Differences between means were analyzed by two-way ANOVA and the Tukey post-test, allowing multiple comparisons. n.s. = non-significant, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Experiment was realized once.

Figure 3




Figure 3. *M. abscessus* R-infected C3HeB/FeJ mice (2.7×10^5 CFU/mouse) treated by Bedaquiline (BDQ), Imipenem (IMP) or BDQ plus IMP. Bacterial loads in the lungs (A), liver (B) and spleen (C) were determined as reported in Fig. 1. Relative weight of spleen to mouse weight are shown in (D). Antibiotic treatment began 2 days after infection. Mice were treated starting on day 2 for 7 days (D12) or 13 days (D20) with twice daily (*i.e.* every 12 h) subcutaneous injection of IMP (MSD laboratories, France) in saline solution at 100 mg/kg or daily oral gavage of BDQ as described in Fig. 2 or both IMP+BDQ. Experimental groups of mice were evaluated for bacterial burden on day 1 (before treatment started), 12 and 20 as described in Fig. 1. (D) Mouse spleens were weighed at 1, 12 and 20 dpi. The value represents the relative weight of each spleen relative to the weight of the mouse from which they were collected. $n = 5$ mice were used per experiment and bacterial load in each group are expressed as log_{10} units of CFU ($\pm$ SD) cells. Differences between means were analyzed by two-way ANOVA and the Tukey post-test, allowing multiple comparisons. n.s. = non-significant, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. Experiment was realized once.

Supplementary Figure 1





Figure 1. (A) Survival of C3HeB/FeJ mice infected intratracheally or intravenously (IV) with *M. abscessus* CIP 104536^T (smooth variant). (B) Persistence of *M. abscessus* in the lungs of intratracheally-infected C3HeB/FeJ mice. Agar beads were prepared as described previously (1). Mice were infected with a solution of agar beads containing 2.10^5 CFUs/mouse in 50 μ l. Survival curves were generated over a 14 days post-infection experiment. Mouse lungs were collected and homogenized, serially diluted and plated onto VCAT (Vancomycin, Colistin sulfate, Amphotericin B, and Trimethoprim) chocolate agar plates (BioMérieux, France) and incubated for 5-6 days at 37°C prior to CFU count. Results are expressed as log₁₀ units of CFU at 1, 14 and 29 dpi. Results are representative of one of two independent experiments (A and B) with similar results.

Supplementary Figure 2



Supplementary Figure 2. Bacterial persistence of *M. abscessus* CIP 104536^T (rough variant) in the lungs, spleen and liver of C3HeB/FeJ mice after infection in the tail vein with 4.8×10^6 (A) and 3.1×10^5 CFU/mouse (B) in a total volume of 200 μ l of water containing 0.9% sodium chloride. The following day, three mice were euthanized and whole organs were harvested to determine baseline bacterial burden. CFU were determined as described in Fig.S1. Results are expressed as the log₁₀ units of CFU at 1, (6), 13 and 20 dpi.

REFERENCES

1. Cigana C, Lorè NI, Riva C, De Fino I, Spagnuolo L, Sipione B, Rossi G, Nonis A, Cabrini G, Bragonzi A. 2016. Tracking the immunopathological response to *Pseudomonas aeruginosa* during respiratory infections. Sci Rep 6:21465.